摘要
目的探讨贝伐珠单抗联合XELOX方案(奥沙利铂+亚叶酸钙+氟尿嘧啶)对胃癌患者T细胞亚群水平的影响。方法选取医院2016年3月至2018年3月收治的胃癌患者130例,按随机数字表法分为对照组和观察组,各65例。两组患者均予XELOX方案进行化疗,观察组患者加用贝伐珠单抗,两组均治疗9周。结果观察组患者的客观缓解率(ORR)和疾病控制率(DCR)分别为73.85%和96.92%,显著高于对照组的47.69%和78.46%(P<0.05);与对照组比较,观察组患者化疗后的CD3+和CD4+细胞水平均显著更高,CD8+细胞水平显著更低,糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、组织多肽特异抗原(TPS)、癌胚抗原(CEA)水平均显著更低,生存质量显著更高(P<0.05);两组患者化疗过程中的不良反应发生率相当(P>0.05)。结论贝伐珠单抗联合XELOX方案治疗胃癌疗效显著,可改善患者的T细胞亚群水平,降低血清肿瘤标志物水平,改善生存质量。
Objective To investigate the effect of bevacizumab combined with XELOX regimen(oxaliplatin+calcium folinate+fluorouracil)on T cell subsets in patients with gastric cancer.Methods Totally 130 patients with gastric cancer admitted to our hospital from March 2016 to March 2018 were selected and divided into the control group and the observation group according to the random number table method,65 cases in each group.The patients in the two groups were given XELOX regimen for chemotherapy,on this basis,the patients in the observation group were treated with bevacizumab.Both groups were treated for 9 weeks.Results The objective remission rate(ORR)and disease control rate(DCR)of the observation group were 73.85%and 96.92%,which were significantly higher than 47.69%and 78.46%of the control group(P<0.05).After chemotherapy,the levels of CD3+and CD4+in the observation group were significantly higher than those in the control group,while the level of CD8+in the observation group was significantly lower than that in the control group(P<0.05).The levels of carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9),tissue polypeptide specific antigen(TPS)and carcinoembryonic antigen(CEA)in the observation group were significantly lower than those in the control group(P<0.05).The quality of life in the observation group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions in the course of chemotherapy was similar between the two groups(P>0.05).Conclusion Bevacizumab combined with XELOX regimen is effective in the treatment of patients with gastric cancer,it can significantly improve the levels of T-cell subsets,reduce the level of serum tumor markers,and improve the quality of life.
作者
郭英
郑峥
邹长鹏
田勍
薄常文
马文华
GUO Ying;ZHENG Zheng;ZOU Changpeng;TIAN Qing;BO Changwen;MA Wenhua(The First Hospital of Hebei Medical University,Shijiazhuang,Hebei,China 050031)
出处
《中国药业》
CAS
2021年第3期28-30,共3页
China Pharmaceuticals
基金
河北省2018年度医学科学研究重点课题[20180255]。
